相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- CAS号:
1637443-98-1
- 规格:
1mg/5mg/10mg/25mg/50mg/100mg/200mg
| 规格: | 1mg | 产品价格: | ¥449.0 |
|---|---|---|---|
| 规格: | 5mg | 产品价格: | ¥1000.0 |
| 规格: | 10mg | 产品价格: | ¥1496.0 |
| 规格: | 25mg | 产品价格: | ¥2504.0 |
| 规格: | 50mg | 产品价格: | ¥3536.0 |
| 规格: | 100mg | 产品价格: | ¥4760.0 |
| 规格: | 200mg | 产品价格: | ¥6296.0 |
Product Introduction
Bioactivity
| 名称 | hVEGF-IN-1 |
| 描述 | hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity. |
| 细胞实验 | MDA-MB-231 cells are plated in the top chambers of 0.8 μm pore trans-wells in Opti-MEM reduced serum medium in the presence or absence of hVEGF-IN-1. Meanwhile, 600 μL of DMEM containing 10% fetal bovine serum (FBS) and 100 μM CoCl2 are added to the lower chambers. The cells are allowed to migrate for 24 h. At the end of the assay, the cells in the top chamber are removed, and the cells at the bottom of the filter are treated by adding 500 μL of DMEM containing 2.5 mg/mL MTT to each well. After incubating at 37 °C with 5% CO2 for 4 h, 500 μL of DMSO is added to each well and the plate is gently rotated for 10 min. Absorbance (570 nm) is measured using a microplate reader. |
| 动物实验 | Mice are separated into three groups: negative control, compound 1-treated, and positive control (doxorubicin-treated). hVEGF-IN-1, doxorubicin, and saline are administered by intraperitoneal injection to athymic nude mice with human tumor xenografts established using MCF-7 breast cancer cells. Mice are injected intraperitoneal once a day for 20 days. Negative controls are injected with 150 μL of saline. The positive control group received doxorubicin by intraperitoneal injection at a dose of 1 mg/kg. hVEGF-IN-1 is similarly administered to mice at a dose of 7.5 mg/kg. After treating the animals for 20 days, the tumor tissues are collected and IHC assays are conducted using an anti-VEGF-A antibody[1]. |
| 体外活性 | hVEGF-IN-1与hVEGF-A mRNA的5′-UTR内富G区域有显著选择性作用并破坏G-四联体结构。hVEGF-IN-1与IRES-A (WT) 绑定(Kd: 0.928 μM),并与发夹DNA绑定(Kd: 21.2 μM)。IRES-A的5′-UTR内G富序列G774-G790对IRES-A的翻译启动活性至关重要。hVEGF-IN-1阻碍BG4与细胞内IRES-A RNA G-四联体的绑定。通过IRES-A mRNA内的G-四联体,hVEGF-IN-1下调hVEGF-A的翻译。hVEGF-IN-1使MDA-MB-231细胞迁移减少至约25%。 |
| 体内活性 | 在携带肿瘤的小鼠中,hVEGF-IN-1能使平均肿瘤体积减少至少于300 mm3。在hVEGF-IN-1存在下,肿瘤重量平均减少60.1%,最终重量达到0.18g,同时,小鼠的体重没有明显变化。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (1.72 mM), Sonication is recommended. DMSO : 5.82 mg/mL (10 mM), Sonication is recommended. |
| 关键字 | VEGFR | VEGF-A | Vascular endothelial growth factor receptor | tumor | quinazoline | migration | IRES-A | Inhibitor | inhibit | hVEGF-IN-1 | hVEGFIN1 | hVEGF IN 1 | G-rich |
| 相关产品 | glycine | Ribociclib | Lenvatinib | Chloramphenicol | Thymoquinone | Regorafenib | Pazopanib | Ethyl cinnamate | Sorafenib | Regorafenib monohydrate | Nintedanib esylate | Albendazole |
| 相关库 | Inhibitor Library | Angiogenesis related Compound Library | Bioactive Compound Library | Bioactive Compounds Library Max | Anti-Colorectal Cancer Compound Library | Kinase Inhibitor Library | Anti-Fibrosis Compound Library | NO PAINS Compound Library | Anti-Lung Cancer Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Prostate Cancer Compound Library |
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验网络 第十九章 杂环化合物和生物碱 杂环化合物在自然界分布很广,其数量几乎占已知有机化合物的三分之一,用途也很多。许多重要的物质如叶绿素、血红素、核酸以及临床应用的一些有显著疗效的天然药物和合成药物等,都含有杂环化合物的结构。生物碱多是中草药的有效成分,绝大多数是含氮的杂环化合物。本章内容与医学关系密切,具有重要意义。
分子中具有高能键的化合物。在生物体内主要有上式(Ⅰ)和(Ⅱ)两种结构的高能化合物。其作用为贮藏能量(例如 ATP、肌酸磷酸)和作为产生 ATP源的中间代谢产物(例如磷酸烯醇丙酮酸)以及合成反应的中间物质(例如酰基辅酶 A),在蛋白质的结构( conformation)变化周期的第一阶段上(例如钠钾 ATP酶的羧基磷酸中间体)也具有重要作用。多数高等化合物具有磷酸基,但也有例外。
由不同种元素组成的纯净物叫做化合物。化合物一般有固定的组成。化合物的组成一般可用化学式表示。化合物具有确定的物理性质和化学性质,不同于其组成元素的性质。化合物中的元素不能用简单的机械方法或物理方法分开,而必须用化学方法才能分离。
技术资料暂无技术资料 索取技术资料








